dc/aml fusion vaccine
Vaccineexperimental
Clinical trial activity
3 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2010 (NCT01096602)
Timeline
Indications
Studied for
Mechanism of action
- Tumor antigensImmunity, active
Tumor antigens immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- dc/aml fusion vaccine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03679650 | Phase 1 | Sep 24, 2018 | Harvard University, National Cancer Institute (NCI) |
| NCT03059485 | Phase 2 | Mar 31, 2017 | Celgene, Harvard University |
| NCT01096602 | Phase 2 | May 1, 2010 | Harvard University, Medivation, National Institutes of Health (NIH), The Leukemia and Lymphoma Society |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Harvard University | Academic/Hospital | 3 | 3 | 2 | 2010 |
| Celgene | For profit | 1 | 0 | 1 | 2017 |
| Medivation | For profit | 1 | 0 | 1 | 2010 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2018 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2010 |
| The Leukemia and Lymphoma Society | Academic/Hospital | 1 | 0 | 1 | 2010 |
6 organizations
Page 1 / 1